Podium to Practice: EHA 2025 – Multiple Myeloma: TRIMM-3 STUDY
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Studies / Trials Discussed
S200 – TALQUETAMAB + CETRELIMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 1B TRIMM-3 STUDY
Studies/trials discussed:
S200 – TALQUETAMAB + CETRELIMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 1B TRIMM-3 STUDY
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.